DEFINIUM THERAPEUTICS, INC.
NASDAQ: DFTX (Definium Therapeutics, Inc.)
Kemas kini terakhir: 7 jam lalu28.34
-1.14 (-3.87%)
Sentimen Berita
AISkor Stockmoo
| Nilai 30% | -1.0 |
| Pulangan di bawah kos modalnya. Pulangan atas modal meningkat. info | |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Sejarah Penilaian info | NA |
| Kesihatan Kewangan info | NA |
| Nilai Pegangan info | NA |
| Premium Risiko info | NA |
| Penilaian Pasaran info | NA |
| Masa 30% | -1.9 |
| Aliran menaik sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info | |
| Aliran menurun: harga di bawah purata bergeraknya, dan purata itu sedang menurun. Harga telah jatuh jauh di bawah purata itu. Dagangan lebih tinggi pada hari harga turun. info | |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Corak Lilin info | NA |
| Sentimen 20% | 0.8 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Berita terkini kebanyakannya positif. info | |
| Sentimen Pegangan info | NA |
| Wang Pintar 20% | 3.4 |
| Institusi bersih +8.02% daripada saham dalam pemfailan 13F terkini: 216 pemegang menambah, 167 mengurang (suku berakhir 30 Sep 2026). info | |
| Kedudukan jual singkat -2.3% dari 31 Aug hingga 30 Oct 2026, 5.8 hari untuk tutup (FINRA). info | |
| Aktiviti Orang Dalam info | NA |
| Keadaan pasaran dan sektor lemah. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor ketinggalan berbanding pasaran. | |
| Tonggak-tonggak tidak sependapat, jadi skor dilemahkan. | |
| Tidak dikira dalam skor | |
| Perolehan sesaham kebanyakannya menurun. Mencatat kerugian dalam tahun-tahun kebelakangan. info | |
| Di bawah garis aliran jangka sederhana. info | |
| Harga hampir dengan purata 52 minggunya. Turun dalam tempoh 5 tahun. info | |
| Momentum jangka pendek menurun. info | |
| Harga hampir dengan paras rintangan. Paras sokongan dan rintangan menurun. info | |
| Skor Akhir | -0.01 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Definium Therapeutics, Inc. | Bercampur | - |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B | Skor |
|---|---|---|---|---|---|
| DFTX | 5 B | - | - | 4.54 | 0.0 |
| SYRE | 9 B | - | - | 10.08 | 1.1 |
| MDGL | 9 B | - | - | 14.74 | -0.4 |
| CORT | 7 B | - | 47.78 | 8.89 | -1.5 |
| FOLD | 5 B | - | - | - | 0.0 |
| TARS | 4 B | - | - | 36.00 | 0.6 |
|
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Capital World Investors | 30 Sep 2026 | 8,255,584 |
| Octagon Capital Advisors Lp | 30 Sep 2026 | 2,511,000 |
| Alliancebernstein L.P. | 30 Sep 2026 | 1,938,303 |
Tiada data dalam julat masa ini.
Institusi
Pemilikan institusi: 92.20%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 216 | 29,390,198 |
| Berkurang | 167 | 18,014,338 |
| Baharu | 70 | 8,825,116 |
| Dijual habis | 70 | 9,208,628 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
Kedudukan Jual Singkat
| Penyelesaian | Saham | Hari untuk tutup |
|---|---|---|
| 30 Oct 2026 | 9,613,993 | 5.8 |
| 15 Oct 2026 | 10,044,279 | 4.9 |
| 30 Sep 2026 | 11,344,959 | 4.9 |
| 15 Sep 2026 | 11,785,195 | 5.2 |
| 31 Aug 2026 | 9,836,400 | 5.6 |
| 14 Aug 2026 | 8,969,420 | 3.4 |
Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 20 Nov 2026 | Yahoo Finance |
Definium Therapeutics Eyes 2027 FDA Filing for LSD-Based Drug, Weighs Two Treatment Paths
Definium Therapeutics (NASDAQ:DFTX) expects to file a new drug application for its lead LSD-based treatment in the first half of 2027, though the company has not settled on whether to seek approval for generalized anxiety disorder, major depressive disorder or both at the outset. CEO Rob Barrow sai… |
| 16 Nov 2026 | Yahoo Finance |
Definium Therapeutics: 3 Key Takeaways for Long-Term Investors
Two encouraging changes from five patients hint at a pipeline beyond depression and anxiety, but the early-stage data leaves open whether DT402 can carry that weight. |
| 16 Nov 2026 | Yahoo Finance |
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Village Farms Posted Record Cannabis Revenue as International Exports Surged 75% Auxly Cannabis Delivered Record Q3 Revenue as Adjusted EBITDA Climbed 29% Key Takeaways; Psychedelic Sector Definium Therapeutics Reported Strong Q3 Results as DT120 Advanced Towards… |
| 12 Nov 2026 | Yahoo Finance |
Is Definium Therapeutics (DFTX) Fully Priced After Positive Phase 3 Results?
Definium Therapeutics has seen its stock price move sharply in recent years, and the surge now raises a straightforward question for investors who care about balance sheet strength. Is the current market value still grounded in Definium Therapeutics' book value, or has the share price pulled… |
| 11 Nov 2026 | Yahoo Finance |
How Investors May Respond To Definium Therapeutics Stock After Phase 3 Success
Definium Therapeutics reported positive Phase 3 data for DT120 in generalized anxiety disorder and major depressive disorder, alongside plans to seek FDA approval after multiple pivotal studies. Recent earnings showed ongoing net losses tied to development spend. The most distinctive angle is that… |
| 11 Nov 2026 | Yahoo Finance |
Definium Therapeutics (DFTX) Following DT120 Phase 3 Data Is The Undervalued Story Intact
Definium Therapeutics (DFTX) is back in focus after reporting third quarter results that showed a reduced quarterly net loss alongside a much larger cumulative loss for the first nine months of 2026. Definium Therapeutics has ridden a sharp re-rating over 2026, with the share price delivering a… |
| 11 Nov 2026 | Yahoo Finance |
Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies
Definium Therapeutics (NASDAQ:DFTX) plans to submit a new drug application to the U.S. Food and Drug Administration for its LSD formulation DT120 in the first half of next year, following positive results from three Phase 3 studies, Chief Medical Officer Daniel Karlin said. The company intends to s… |
| 10 Nov 2026 | Yahoo Finance |
Definium Therapeutics Inc (DFTX) (Q3 2026) Earnings Call Highlights: $1. ...
Definium Therapeutics Inc (DFTX) pairs a cash runway into 2030 with two FDA breakthrough therapy designations for DT120 and a planned first-half 2027 NDA filing, even as R&D and G&A spending climb. |
| 09 Nov 2026 | Yahoo Finance |
Definium (DFTX) Q3 2026 Earnings Call Transcript
Phase 3 wins set up a 2027 filing and a commercial push. |
| 09 Nov 2026 | Yahoo Finance |
What Definium Therapeutics (DFTX) Said on Its Q3 Earnings Call
Definium Therapeutics (NASDAQ:DFTX) plans to file a new drug application for its psychiatric treatment candidate DT120 ODT in the first half of 2027, following positive results from three Phase 3 studies in generalized anxiety disorder and major depressive disorder, executives said on the company’s… |
| 09 Nov 2026 | Yahoo Finance |
Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
NEW YORK, November 09, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company") (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported… |
| 09 Nov 2026 | Yahoo Finance |
Definium Therapeutics Announces New Employee Inducement Grants
NEW YORK, November 09, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of… |
| 04 Nov 2026 | Yahoo Finance |
Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
NEW YORK, November 04, 2026--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced four… |
| 03 Nov 2026 | Yahoo Finance |
Definium Therapeutics to Participate at Upcoming Investor Conferences
NEW YORK, November 03, 2026--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that… |
| 29 Oct 2026 | Yahoo Finance |
Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
NEW YORK, October 29, 2026--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a webcast at 4:30… |
| 19 Oct 2026 | Yahoo Finance |
Definium Therapeutics (DFTX) Stock May Trade Above Fair Value On Book Value
Definium Therapeutics has seen its share price move sharply in recent years, which puts a spotlight on whether the current US$32.97 level is supported by the book value on its balance sheet. With such a strong price story already on the table, investors are asking how much of that journey is… |
| 30 Sep 2026 | Yahoo Finance |
Jefferies Highlights Three Biotech Stocks With Blockbuster Potential
Investing.com -- Jefferies identified three biotechnology stocks that appear undervalued with strong commercial prospects despite a challenging macro environment. The firm noted that rising interest rates are pressuring small and mid-cap biotech companies, potentially shifting investor focus toward… |
| Papar semua | ||
Persediaan Teknikal Sederhana
AI Analisis Teknikal
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |